Evidence map›Paper›PMID 41437733›Full record

ArticleMolecular oncology2026

Phenotypic and genotypic characterization of single circulating tumor cells in the follow-up of high-grade serous ovarian cancer.

Carolin Salmon, Rui P L Neves, Nikolas H Stoecklein, Sven-Thorsten Liffers, Jens Siveke, Jan D Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir-Bauer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carolin SalmonDepartment of Gynecology and Obstetrics, University Hospital Essen, Germany.
Rui P L NevesDepartment of General, Visceral and Pediatric Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Germany.ORCID 0000-0002-4515-739X
Nikolas H StoeckleinDepartment of General, Visceral and Pediatric Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Germany.ORCID 0000-0002-3412-594X
Sven-Thorsten LiffersWest German Cancer Center, Bridge Institute of Experimental Tumor Therapy, University Medicine Essen, Germany.
Jens SivekeWest German Cancer Center, Bridge Institute of Experimental Tumor Therapy, University Medicine Essen, Germany.
Jan D KuhlmannDepartment of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.ORCID 0000-0003-3820-3017
Pauline WimbergerDepartment of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Paul BuderathDepartment of Gynecology and Obstetrics, University Hospital Essen, Germany.
Rainer KimmigDepartment of Gynecology and Obstetrics, University Hospital Essen, Germany.
Sabine Kasimir-BauerDepartment of Gynecology and Obstetrics, University Hospital Essen, Germany.ORCID 0000-0002-8081-1799

Funding

Deutsche Krebshilfe 70113616
6 · The paper itself

Abstract

Single circulating tumor cell (sCTC) analysis enables the determination of predominant CTC phenotypes and genotypes. We previously demonstrated the feasibility of sCTC detection and genomic characterization in high-grade serous ovarian cancer (HGSOC) by combining immune-magnetic enrichment and image-based sorting, followed by whole-genome amplification (WGA) and next-generation sequencing-based copy number alteration analysis (CNA). Here we aimed to improve our workflow by incorporating HGSOC-specific markers, folate receptor alpha (FRα), and markers to identify epithelial (cytokeratin) and mesenchymal (vimentin) phenotypes for the phenotypic as well as genotypic analysis of sCTCs over the course of treatment in 42 HGSOC patients. We detected a significant reduction of FRα-positive cells (P = 0.0205) and an expansion of cells with a high nuclear staining and no target antigen expression (P = 0.002). Before treatment, sCTCs showed an enrichment in CNAs of Chromosomes 2, 7, and 12, while CNA dynamics of sCTCs suggested a potential selection of distinct CNAs specific to the homologous recombination pathway. sCTCs revealed persistent CNAs in the CDK4 and emerging ones in the ALK oncogene. Notably, primary tumors revealed considerable fractions of shared genomic aberrations.

Indexed as

Cystadenocarcinoma, SerousNeoplastic Cells, CirculatingOvarian NeoplasmsAgedBiomarkers, TumorDNA Copy Number VariationsFemaleFolate Receptor 1Follow-Up StudiesGenotypeHumansMiddle AgedNeoplasm GradingPhenotypeSingle-Cell AnalysisBiomarkers, TumorFolate Receptor 1genotypehigh‐grade serous ovarian cancerphenotypesingle cell sequencingsingle circulating tumor cells

Identifiers

PMID41437733
PMCPMC13238577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.